Hosted on MSN
Typhoid conjugate vaccine demonstrates strong safety and immunogenicity in Phase III trial
Phase III results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj. Multi-dose, demonstrate that it is safe and immunogenic in typhoid-endemic populations in sub-Saharan Africa ...
PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj. ® Multi-dose is manufactured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results